Tealwood Asset Management Inc. Purchases New Holdings in ADMA Biologics Inc $ADMA

Tealwood Asset Management Inc. acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 72,087 shares of the biotechnology company’s stock, valued at approximately $1,315,000.

Several other large investors have also recently bought and sold shares of ADMA. State Street Corp boosted its position in ADMA Biologics by 5.6% in the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock valued at $219,950,000 after buying an additional 637,727 shares during the last quarter. Westfield Capital Management Co. LP bought a new stake in shares of ADMA Biologics during the third quarter worth $74,866,000. Dimensional Fund Advisors LP raised its position in shares of ADMA Biologics by 0.7% during the third quarter. Dimensional Fund Advisors LP now owns 4,798,274 shares of the biotechnology company’s stock worth $70,343,000 after acquiring an additional 35,199 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of ADMA Biologics by 1.8% during the third quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock valued at $68,842,000 after acquiring an additional 84,934 shares during the period. Finally, Thrivent Financial for Lutherans lifted its stake in shares of ADMA Biologics by 24.9% during the third quarter. Thrivent Financial for Lutherans now owns 4,141,840 shares of the biotechnology company’s stock valued at $60,719,000 after acquiring an additional 826,415 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Performance

Shares of ADMA Biologics stock opened at $14.32 on Friday. The firm has a fifty day moving average of $16.33 and a two-hundred day moving average of $16.64. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. The stock has a market capitalization of $3.41 billion, a price-to-earnings ratio of 23.87 and a beta of 0.51. ADMA Biologics Inc has a 52 week low of $13.76 and a 52 week high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business had revenue of $139.16 million for the quarter, compared to analyst estimates of $139.80 million. During the same period last year, the company earned $0.46 EPS. The firm’s revenue was up 18.4% on a year-over-year basis. As a group, equities research analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current year.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the transaction, the chief operating officer owned 466,600 shares in the company, valued at approximately $7,292,958. This trade represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms bought 7,000 shares of ADMA Biologics stock in a transaction on Thursday, March 5th. The shares were bought at an average price of $15.67 per share, for a total transaction of $109,690.00. Following the acquisition, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 3.50% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.